BioWorld

Oct. 16, 2003

With Increasing Product Sales, Genzyme Beats Q3 Estimates

Genzyme Corp. beat consensus earnings estimates for the third quarter, without taking into account the company's purchase of SangStat Medical Corp., and raised its fourth-quarter and year-end financial outlook. (BioWorld Today) Read More

U.S.-Approved Human Embryonic Stem Cells Recruited To Generate Transplantable Scarcity Of Organs

Immunex, Abgenix Revise Plans To Advance ABX-EGF For Cancer

Correction

Favrille Raises $10.6M To Push NHL Product To Phase III Trial

Sunesis In-Licenses Cancer Compound From Dainippon

Other News To Note

Biotech Comes On Strong: 'Second-Best' Year Ever?

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...